Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31704110 | 0.83 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL31704153 | 0.83 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL2107934 | 0.83 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL19370870 | 0.74 | CRBN (0.81) | CRBNDDB1POLB | |
| SCHEMBL13210441 | 0.71 | DDB1 (0.57) | CRBNDDB1CTRB1PDGFRAPRKACA | |
| SCHEMBL5322391 | 0.71 | DDB1 (0.47) | CRBNDDB1CTRB1PDGFRAPRKACA | |
| SCHEMBL1567424 | 0.71 | DDB1 (0.67) | CRBNDDB1 | |
| SCHEMBL3730431 | 0.71 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL8300066 | 0.71 | DDB1 (0.67) | CRBNDDB1 | |
| SCHEMBL13758369 | 0.71 | DDB1 (0.56) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | CRBN 37/4885DDB1 292/4885POLB 2996/4885 |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | CRBN 252/4885DDB1 510/4885POLB 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.